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ABSTRACT
Image-guided radiotherapy (IGRT) is an essential tool in the accurate delivery of modern radiotherapy techniques.
Prostate radiotherapy positioned using skin marks or bony anatomy may be adequate for delivering a relatively
homogeneous whole-pelvic radiotherapy dose, but these surrogates are not reliable when using reduced margins, dose
escalation or hypofractionated stereotactic radiotherapy. Fiducial markers (FMs) for prostate IGRT have been in use since
the 1990s. They require surgical implantation and provide a surrogate for the position of the prostate gland. A variety of
FMs are available and they can be used in a number of ways. This review aimed to establish the evidence for using
prostate FMs in terms of feasibility, implantation procedures, types of FMs used, FM migration, imaging modalities used
and the clinical impact of FMs. A search strategy was defined and a literature search was carried out in Medline. Inclusion
and exclusion criteria were applied, which resulted in 50 articles being included in this review. The evidence demonstrates
that FMs provide a more accurate surrogate for the position of the prostate than either external skin marks or bony
anatomy. A combination of FM alignment and soft-tissue analysis is currently the most effective and widely available
approach to ensuring accuracy in prostate IGRT. FM implantation is safe and well tolerated. FM migration is possible but
minimal. Standardization of all techniques and procedures in relation to the use of prostate FMs is required. Finally,
a clinical trial investigating a non-surgical alternative to prostate FMs is introduced.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed
cancer in males and is often treated with radical external
beam radiotherapy. Advances in linear accelerator technol-
ogy and treatment planning software have made it possible
to deliver highly conformal radiation dose distributions us-
ing techniques such as intensity-modulated radiotherapy
(IMRT). Dose escalation studies have demonstrated im-
proved outcomes for patients with PCa increasingly using
hypofractionated stereotactic radiotherapy to exploit the
sensitivity of PCa to large doses per fraction.1–4 Image-
guided radiotherapy (IGRT) is considered an essential tool
in ensuring the safe clinical application of these techniques.
Prostate radiotherapy positioned with reference skin marks
and/or aligned to bony anatomy is dependent on stability
and reproducibility. This may be adequate for delivering
a relatively homogeneous dose to large pelvic ﬁelds. How-
ever, it is not a reliable approach for IMRT, volumetric arc
therapy, dose-escalated or hypofractionated stereotactic
treatment. Collectively, these advanced techniques require
a greater degree of precision, given the decreased margin for
error and the potential for radiation injury from overdosing
critical structures or treatment failure due to underdosing
the target. With the exception of MRI-guided treatment,
technological advances which enable complex planning and
delivery have surpassed that which aims to verify target
position or dose delivery in patients. Two-dimensional (2D)
megavoltage (MV) or kilovoltage (kV) prostate IGRT is re-
liant on pelvic bone alignment and while cone-beam CT
(CBCT) enables three-dimensional (3D) imaging, prostate
gland visualization remains challenging owing to inadequate
soft-tissue contrast. Internal organ motion adds to the
challenge of accurately targeting the prostate and is a limit-
ing factor in margin reduction and dose escalation.
Fiducial markers (FMs) surgically implanted within the
prostate gland prior to radiotherapy planning have been
developed to improve contrast and therefore treatment
setup and prostate targeting. Where employed in clinical
practice, there are a variety of approaches in relation to
how prostate FMs are utilized. This article aimed to review
the evidence for the use of FMs in prostate IGRT in re-
lation to feasibility and efﬁcacy, implantation, number and
type of FMs, migration, imaging modalities used and
clinical impact. Furthermore, it outlines current evidence
on a natural alternative to FMs and introduces a recently opened
clinical trial investigating this.
METHODS AND MATERIALS
A literature search was carried out in Medline using the search
strategy outlined in Figure 1.
Results of the initial literature search were subject to the fol-
lowing selection criteria:
• Inclusion criteria: studies on humans, speciﬁcally investigating
the technical aspects or clinical efﬁcacy of FMs for prostate
IGRT; studies of prostate motion based on FMs
• Exclusion criteria: review articles, studies of ,20 patients
(where treatment setup data are reported), phantom studies,
post-prostatectomy treatments.
Limiting articles to those reporting setup data on at least
20 patients resulted in a signiﬁcant number of articles being
automatically excluded from this review. This is justiﬁed on the
basis that published guidance states that at least 20 patients and
preferably 25 patients should be included in such studies to be
representative of a given patient population and technique.5
A summary of the studies included in the review is presented
in Table 1.
FIDUCIAL MARKERS FOR PROSTATE IMAGE-
GUIDED RADIOTHERAPY
Feasibility and efficacy
The feasibility and efﬁcacy of using FMs for prostate IGRT has
been documented in the literature.6–11
Before in-room imaging was widely available, Crook et al6
demonstrated signiﬁcant prostate gland motion based on FM
positions relative to bony landmarks on repeat CT scans in
a study of 55 patients. They found the average prostate dis-
placement in the posterior and inferior directions to be 6mm
and that 30% had displacements .10mm posteriorly, which
standard treatment planning margins would not have encom-
passed. They strongly recommended the use of implanted FMs
for treatment setup veriﬁcation as opposed to alignment using
bony landmarks.
Crook et al ﬁndings6 from 1995 were supported by Schallenkamp
et al9 in 2005 using MV electronic portal imaging (MV EPI) and
digitally reconstructed radiographs, and then reconﬁrmed in 2013
by Paluska et al11 using modern planning and imaging techniques.
Paluska et al acquired weekly CBCT scans following setup to
retrospectively reconstruct and verify dose delivered to patients
receiving IMRT to the prostate with a simultaneous integrated
boost to the proximal seminal vesicles (SVs). For bone setup
using a 10-mm clinical target volume (CTV)–planning target
volume (PTV) margin, inadequate prostate coverage was ob-
served in 5 out of 29 patients, resulting in underdosing of the
target. Despite a reduced CTV–PTV margin, the prostate
coverage for FM-based setup was better. Schallenkamp et al
and Paluska et al both proposed that prostate FMs, when used
with a daily online imaging correction protocol, facilitate
CTV–PTV margin reduction.
The largest study on the reliability of FMs was reported in
a retrospective analysis of daily treatment setup data from
453 patients treated with IMRT using an ofﬂine correction
protocol by van der Heide et al.12 They reported minimal
marker migration, accurate marker detection and time trends in
relation to prostate motion but recommended caution when
considering reducing planning margins owing to other sources
of uncertainty such as target delineation and SV motion.
Much of the evidence in relation to prostate motion is based on
setup data acquired using FM position measured using a range
of imaging modalities. Nine studies investigating prostate mo-
tion and otherwise satisfying the search criteria were included.
In a study of 427 patients undergoing prostate IMRT treated
using FM IGRT, Kotte et al13 observed intrafraction motion
.2mm in a time frame of 5–7min in 66% of patients. No
correlation was found between fraction number and degree of
motion. Motion was more frequent in the anteroposterior (AP)
and superior–inferior directions. They recommended the use of
FMs for prostate treatment setup and at least a 2-mm margin to
account for intrafraction motion, not including other sources of
Figure 1. Medline search strategy.
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Table 1. Summary of studies included in review
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
Feasibility
Prostate motion
during standard
radiotherapy as
assessed by FMs
Crook et al6 1995 Retrospective cohort 55
Signiﬁcant prostate
motion during
radiotherapy.
Recommend using
markers and EPIDs
to verify position
of target
Technical aspects of
daily online
positioning of the
prostate for 3D
conformal
radiotherapy using
an EPI device
Herman et al7 2003
Prospective
feasibility
20
EPID and
intraprostatic
markers can be used
to precisely localize
and correct
variations in target
position following
setup to external
reference marks
Feasibility of
insertion/
implantation of
2.0-mm-diameter
gold internal FMs
for precise setup and
real-time tumour
tracking in
radiotherapy
Shirato et al8 2003
Prospective
feasibility
93 (31 prostate)
Internal FMs can be
safely inserted into
various organs.
Three-marker
method has
been shown to
be useful for
spinal/paraspinal
and prostate
setup
Prostate position
relative to pelvic
bony anatomy based
on intraprostatic
gold markers
and EPI
Schallenkamp
et al9
2005
Prospective
feasibility
20
Independent
prostate motion is
signiﬁcant. FMs
within the prostate
are stable and
facilitate margin
reduction
A comparison of the
use of bony anatomy
and internal
markers for ofﬂine
veriﬁcation and an
evaluation of the
potential beneﬁt of
online and ofﬂine
veriﬁcation
protocols for
prostate
radiotherapy
McNair et al10 2008
Retrospective
analysis
30
FMs and an ofﬂine
imaging protocol
are effective in
reducing
systematic errors
Utilization of CBCT
for reconstruction
of dose distribution
delivered in IGRT of
prostate carcinoma
—bony landmark
setup compared
with FM setup
Paluska et al11 2013
Retrospective
analysis
59
PTV margin
reduction is feasible
using FMs for image
guidance
Analysis of
FM-based position
veriﬁcation in EBRT
of patients with PCa
Van der
Heide et al12
2007
Retrospective
analysis
453
FMs are stable.
Identiﬁed time
trends in
prostate motion
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
Prostate
motion
Intrafraction
motion of the
prostate during
EBRT: analysis of
427 patients with
implanted FMs
Kotte et al13 2007
Retrospective
analysis
427
Frequent prostate
motion observed
during EBRT, which
can be encompassed
with
a 2-mm margin
IMRT using
implanted FMs with
daily portal imaging:
assessment of
prostate
organ motion
Chen et al14 2007
Retrospective
analysis
33
Prostate motion is
signiﬁcant. Daily
imaging with FMs is
necessary for the
reduction of
margins
Intrafraction
prostate
displacement in
radiotherapy
estimated from pre-
and post-treatment
imaging of patients
with implanted FMs
Kron et al15 2010
Retrospective
analysis
184
Prostate motion is
a limiting factor
when considering
margins for
radiotherapy
Intrafraction
motion during
extreme
hypofractionated
radiotherapy of the
prostate using pre-
and post-treatment
imaging
Quon et al16 2012 Phase I/II trial 53
Prostate
displacements
during
hypofractionated
radiotherapy are
comparable with
intrafraction
conventionally
fractionated
treatments
Intrafractional
motion of the
prostate during
hypofractionated
radiotherapy
Xie et al17 2008
Retrospective
analysis
21
With monitoring
and intervention
prostate motion
within the range of
the Cyberknife
tracking range;
however, there
is signiﬁcant
variation between
patients
Deformation of
prostate and SVs
relative to
intraprostatic FMs
Van der
Weilen et al18
2008
Prospective
clinical study
21
With respect to
FMs, prostate
deformation is
small, SV
deformation
considerable
An MRI study of
prostate
deformation relative
to implanted
gold FMs
Nichol et al21 2007
Prospective
clinical study
25
During
radiotherapy, FMs
in-migrated and
prostate volume
decreased. Patients
undergoing TURP
demonstrated
greater
deformation than
those not
undergoing TURP
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
Hybrid registration
of prostate and SVs
for IGRT
De Boer et al19 2013
Retrospective
analysis
20
Substantial
differences observed
between SV and
prostate orientations
Margin evaluation
in the presence of
deformation,
rotation and
translation in
prostate and entire
SV irradiation with
daily marker-based
setup corrections
Mutanga et al20 2011 Retrospective study 21
PTV margins based
on FM, prostate
5mm and .8mm
for SVs. Correction
of rotational errors
of little beneﬁt
Implantation
Technique for
implantation of FMs
in the prostate
Shinohara and
Roach22
2008 Retrospective study 705
TRUS-guided FM
implantation is well
tolerated.
Experience provides
a guide for clinicians
Technique of
outpatient
placement of
intraprostatic FMs
before EBRT
Linden et al23 2009 Retrospective study 98
TRUS-guided FM
implantation is safe
and efﬁcacious
Implantation of
FMs for image
guidance in prostate
radiotherapy:
patient-reported
toxicity
Igdem et al24 2009
Prospective
clinical study
177
TRUS-guided FM
implantation is safe
and well tolerated
Patient-reported
complications from
FM implantation for
prostate IGRT
Gill et al26 2012
Retrospective study
(questionnaires)
234
TRUS-guided FM
insertion for IGRT is
well tolerated in the
majority of patients
with PCa
Is periprostatic
nerve block a gold
standard in case of
TRUS-guided
prostate biopsy?
Kumar et al27 2013
Prospective
randomized
double-blinded
placebo-controlled
study
150
Periprostatic nerve
block provides
better pain control
in TRUS-guided
prostate biopsy, but
still there is need of
additional analgesic
in the form of
tramadol or INB.
Tramadol has
advantage of oral
intake and analgesic
effect at time of
probe insertion and
at nerve block. Both
tramadol and INB
may be used in
combination along
with PNB
Ultrasound-guided
TR implantation of
gold markers for
Langenhuijsen
et al28
2007
Retrospective
analysis
209
TR gold marker
implantation well
tolerated. Moderate
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
prostate localization
during EBRT:
complication rate
and risk factors
complication rate
inﬂuenced by
disease stage, ADT
and age
Single-centre
experience in
prostate ﬁducial
placement:
technique and
mid-term follow-up
Kably et al30 2014
Retrospective
analysis
75
TR ultrasound
guidance of FMs is
feasible, well
tolerated and safe
Long-term
experience with TR
and TP
implantations of
gold FMs in the
prostate for position
veriﬁcation in
EBRT; feasibility,
toxicity and quality
of life
Moman et al33 2010
Retrospective
analysis
914
Clinical use of
TP-implanted gold
FMs for position
veriﬁcation in EBRT
for PCa is a feasible
and safe procedure
without inﬂuencing
patient quality of life
Infections after FM
implantation for
prostate
radiotherapy: are we
underestimating
the risks?
Loh et al31 2015
Retrospective
analysis
285
Overall rate of
symptomatic
infection with FM
implantation is
higher than other
FM series at 7.7%.
This is in keeping
with prostate biopsy
reports of infection
Number and
type of FM
Improving
positioning in
high-dose
radiotherapy for
PCa: safety and
visibility of
frequently used
gold FMs
Fonteyne
et al35
2012 Prospective RCT 25
Stability and
visibility of ﬁve
different types of
marker was proven.
Larger markers
facilitate automatic
image fusion;
however; they
generate more
scatter than smaller
markers
Feasibility,
detectability and
experience with
platinum seed
internal FMs for
CT–MRI fusion and
real-time tumour
tracking
during SABR
Janardanan
et al38
2012 Retrospective study 29
Platinum seeds
provide superior
contrast to gold
seeds on MR images
and a better choice
for CT–MRI fusion
Clinical results from
ﬁrst use of prostate
stent as FM for
radiotherapy of PCa
Carl et al44 2011
Prospective
clinical study
62
Ni–Ti stents have
potential as new
prostate FM
Inﬂuence of the
number of
elongated FMs on
De Boer et al42 2012 Retrospective study 24
Two elongated
markers placed at
either side of the
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
the localization
accuracy of the
prostate
prostate can be used
to accurately localize
the prostate
for IGRT
Multi-institutional
clinical experience
with the Calypso
system in localization
and continuous,
real-time monitoring
of the prostate gland
during external
radiotherapy
Kupelian
et al46
2007
Prospective
clinical study
41
Using three
implanted
electromagnetic
transponders
provides clinically
efﬁcient, accurate and
objective localization
of the prostate
Patient positioning
based on a radioactive
tracer implanted in
patients with localized
PCa: a performance
and safety evaluation
De
Kruijf et al48
2013
Prospective
single-arm
multi-institutional
study
20
Implantation of the
tracer is safe and
feasible and patients
can be positioned and
monitored accurately
using RealEye
Migration
(Non)-migration of
radiopaque markers
used for online
localization of the
prostate with an
EPI device
Pouliot et al29 2003
Retrospective
analysis
10
None of the markers
studied migrated
signiﬁcantly. The
use of three markers
provides a tool to
monitor prostate
position and volume
changes that can
occur over time
owing to hormone
or radiation therapy
Marker seed
migration in
prostate localization
Poggi et al49 2003
Prospective
clinical study
9
Negligible seed
migration over the
course of
radiotherapy
Intraprostatic
ﬁducials for
localization of the
prostate gland:
monitoring IMDs
during radiation
therapy to test for
marker stability
Kupelian
et al50
2005
Retrospective
analysis
56
Seed migration
within the prostate
during a course of
radiotherapy is
negligible. Prostate
deformation rather
than true migration
results in observed
marker position
variations
Migration of
intraprostatic FMs
and its inﬂuence on
the matching quality
in EBRT for PCa
Delouya et al51 2010
Retrospective
analysis
31
Average daily seed
migration is often
negligible.
Migration .2mm
from planning to
ﬁrst treatment may
require adjustment
of PTV margin to
account for this
Impact of
concurrent
androgen
Tiberi et al52 2012
Retrospective
analysis
37
A delay between the
start of ADT and the
start of EBRT;
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
deprivation on FM
migration in EBRT
for PCa
prostate involution
has little or no effect
on FM positioning
within the gland.
,1% of treatments
studied
demonstrated
signiﬁcant marker
migration
Imaging
modality
used
IGRT for PCa
comparing kV
imaging of FMs
with CBCT
Barney et al56 2011 Retrospective study 36
Target veriﬁcation
for CBCT and kV
imaging using FMs
are similar; however,
over 25% of shifts
differed enough to
affect target
coverage
EPI vs kV imaging
in FM IGRT for
PCa: an analysis of
setup uncertainties
Gill et al41 2012 Prospective 333
Suggests a larger
CTV–PTV margin is
used in EPI-based
IGRT for PCa
Method comparison
of ultrasound and
kV X-ray FM
imaging for prostate
radiotherapy
targeting
Fuller et al61 2006
Prospective
non-randomized
study
40
Signiﬁcant
differences in
ultrasound and FM
IG setup data. Data
between ultrasound
and FM imaging not
interchangeable
Study of ExacTrac
X-ray 6D IGRT
setup uncertainty
for marker-based
prostate IMRT
treatment
Shi et al60 2012 Retrospective study 43
Overall interfraction
mean error of 2mm
or less for 3D
translations and
0.25° rotation,
facilitating margin
reduction
Comparison of daily
MV EPI or kV
imaging with
marker seeds with
ultrasound imaging
or skin marks for
prostate localization
and treatment
positioning in
patients with PCa
Serago et al43 2006 Retrospective study 35
MV and kV EPI
similar in terms of
accuracy and
superior to
ultrasound
Comparison of
ultrasound and
implanted seed
marker prostate
localization
methods:
implications
for IGRT
Scarbrough
et al62
2006
Retrospective
analysis
40
Ultrasound and FM
setup data differ
signiﬁcantly,
resulting in different
PTV margins. More
variation is seen in
ultrasound data
Comparison of
TAUS and
electromagnetic
Foster et al63 2010
Retrospective
analysis
41
Ultrasound and
electromagnetic
transponder setup
(Continued)
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Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
transponders for
prostate localization
data differ
signiﬁcantly.
Ultrasound-derived
PTV margins 3–4
times smaller than
Calypso data
Clinical
impact
Individualized PTVs
for intrafraction
motion during
hypofractionated
IMRT boost for PCa
Cheung et al64 2005
Prospective
clinical study
33
Acute toxicity using
IMRT for
hypofractionated
boost was
acceptable. Grade 3
urinary toxicity may
be increased
compared with
standard
fractionation
PTV margins for
prostate
radiotherapy using
daily EPI and
implanted FMs
Skarsgard
et al65
2010
Prospective Phase
I/II study
46
Daily image
guidance with FMs
allows signiﬁcant
reduction of PTV
margin, facilitating
dose escalation
which may
improve outcomes
for patients
with PCa
Does IGRT improve
toxicity proﬁle in
whole pelvic-treated
high-risk PCa?
Chung et al68 2009 Prospective study 25
Rectal and bladder
toxicity consistently
lower for
FM-guided
radiotherapy group
than that for
non-FM-guided
radiotherapy. This
is likely attributable
to reduced PTV
margins in
the FM-guided
group
Treatment-related
morbidity in PCa:
a comparison of 3D
conformal radiation
therapy with and
without image
guidance using
implanted FMs
Singh et al69 2013 Retrospective study 282
A signiﬁcant
reduction in bowel
dysfunctional
symptoms reported
by the IGRT group
vs the
non-IGRT group
Treatment outcome
of high-dose
IG-IMRT using
intraprostate FMs
for localized PCa at
a single institute
in Japan
Takeda et al67 2012 Retrospective study 141
High-dose
FM-guided IMRT
well tolerated
Late toxicity and
biochemical control
in 554 patients with
Kok et al71 2013 Retrospective study 186
FM-guided IGRT
associated with
a reduction in late
(Continued)
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uncertainty. These ﬁndings are supported by data from other
studies of prostate motion also based on FMs.14,15
FMs have been employed in assessing the increased precision re-
quired for stereotactic ablative radiotherapy. Quon et al,16 using pre-
and post-treatment 2D kV imaging of prostate FMs, concluded that
intrafraction motion is small and that the degree of motion observed
indicates that the time taken for delivery of step-and-shoot IMRT
did not signiﬁcantly increase prostate motion. However, it is possible
that transient prostate displacements may have gone undetected.
This idea is supported by Xie et al,17 who described another ap-
proach to monitoring FM position using stereoscopic (SC) X-ray
imaging during treatment and pausing treatment if outside a pre-
deﬁned threshold. They found signiﬁcant motion with an image
sampling rate of every 40 s and suggest a higher sampling rate may
be appropriate for some patients. These ﬁndings would indicate that
prostate motion is more signiﬁcant than observed by Quon et al16
and also that pre- and post-treatment images may not be adequate
to assess intrafraction motion.
FMs combined with online correction can minimize the un-
certainty associated with aligning the prostate for IGRT and act
as an aid to assessing the impact of prostate intrafraction mo-
tion. However, the evidence suggests that the method used to
assess motion using FMs can produce varying results and
therefore, changes to dose, planning margins and correction
protocols should allow for this.
Online correction based on prostate FM position will not nec-
essarily ensure coverage of other critical structures, for example
SVs, if included in the PTV. Van der Wielen et al18 used FMs to
investigate prostate and SV deformation. In their study of
21 patients, analyzing prostate contours relative to FM position
on repeat CT scans, they found prostate deformation to be small
[standard deviation (SD)# 1mm] and SV deformation, relative
to FMs, signiﬁcant (SD# 3mm). De Boer et al19 also report
signiﬁcant differences in the position of the prostate and SVs
and describe a method in which SVs are included to ensure
registration of both based on CBCT imaging. FM corrections are
generally translational corrections only. Despite the differences
reported in prostate and SV deformation, the addition of a ro-
tational correction has been shown to allow only a modest re-
duction in planning margins.18,20
Nichol et al21 used repeat MRI scans to assess prostate de-
formation relative to FMs in 25 patients and suggest that FMs
are a good surrogate in the left–right direction but not as good
in the AP or craniocaudal directions. They identiﬁed isolated
cases of large changes in prostate volume and shape and suggest
that increases in prostate volume may result in a geographic miss
if using reduced margins.
The evidence spanning almost 20 years would indicate that
alignment to FMs is feasible and more effective at localizing the
prostate for radiotherapy than alignment to external skin marks
or bony anatomy on planar imaging.
FIDUCIAL MARKER IMPLANTATION
Implantation of FMs into the prostate involves a surgical procedure
which carries associated risks including pain, bleeding, inﬂammation
and infection, but on balance, it is safe and well tolerated.
There are two main approaches: transrectal (TR) or trans-
perineal (TP), both usually under TR ultrasound (TRUS)
guidance. ATR technique is proposed by Shinohara and Roach22
as suitable for insertion of gold markers and electromagnetic
transponders. The technique, developed over 10 years with
705 patients, is similar to a TRUS-guided biopsy procedure.
Table 1. (Continued)
Focus Title Authors
Year of
publication
Study type
Number of
patients/
subjects
Main
conclusions
PCa treated with
and without
dose-escalated IGRT
urinary toxicity and
improved
biochemical tumour
control. Further
studies required
Improvement in
toxicity in patients
at high risk of PCa
treated with
IG-IMRT compared
with 3D conformal
radiotherapy
without daily image
guidance
Sveistrup
et al72
2014 Retrospective study 311
FM-IGRT can be an
effective method of
reducing GI and GU
toxicity when
treating PCa
3D, three-dimensional; ADT, androgen deprivation therapy; CBCT, cone-beam CT; CTV, clinical target volume; EBRT, external beam radiotherapy; EPI,
electronic portal imaging; EPID, electronic portal imaging device; FM, fiducial marker; GI, gastrointestinal; GU, genitourinary; IG, image-guided;
IG-IMRT, image-guided intensity-modulated radiotherapy; IGRT, image-guided radiotherapy; IMD, intermarker distance; IMRT, intensity-modulated
radiotherapy; INB, intraprostatic nerve block; kV, kilovoltage; MV, megavoltage; PCa, prostate cancer; PNB, periprostatic nerve block; PTV, planning
target volume; RCT, randomized controlled trial; SABR, stereotactic ablative radiotherapy; SV, seminal vesicle; TAUS, transabdominal ultrasound;
TP, transperineal; TR, transrectal; TRUS, transrectal ultrasound; TURP, transurethral resection of the prostate.
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They reported one case of urinary tract infection and no cases of
bleeding or haematuria. Linden et al23 also report no compli-
cations using a similar technique in a retrospective review of
98 males.
Both studies describe preparation including prophylactic anti-
biotics, rectal enemas, cessation of anticoagulant/antiplatelet
medication, local anaesthesia and preparation of markers and
both employed a triangular arrangement of markers, i.e. right
base, left mid-gland or base and right apex. Shinohara and
Roach highlight the importance of avoiding of the urethra to
ensure markers are not subsequently lost to voiding. They also
refer to “tenting” of the prostate by the needle, which on TRUS
may give the appearance of being in the prostate when in fact the
needle has not penetrated the capsule. This, as well as placing
within the urethra, may explain the “loss” of some markers
reported by other investigators.6,24
Igdem et al24 prospectively quantiﬁed patient-reported mor-
bidity with 135 out of 177 patients completing a questionnaire
relating to side effects from TRUS-guided TR implantation of 3
gold FMs. No anaesthesia was used. 5 patients reported rectal
bleeding and haematuria was experienced by 20 patients, al-
though none required additional medication or intervention.
Three patients experienced urinary infection requiring addi-
tional antibiotics. Using the Wong Baker pain scale,25 36% of
patients indicated 2 (mild) on a 0–5 scale and the mean pain
score was 1.7. Gill et al26 reported on 234 patients undergoing
the same TRUS TR procedure with the addition of a peripro-
static nerve block, which is considered the gold standard for
TRUS-guided prostate biopsy.27 Of those patients who gave
a pain score, only 21.9% of patients in total scored pain at 2 or
higher and 75% patients scored pain as 1 or 0 (very mild or no
pain), and the mean pain score was lower than that observed by
Igdem et al at 1.1.
Langenhuijsen et al28 reported on 209 patients who underwent
TRUS TR implantation of 4 gold markers without a preceding
enema or local anaesthesia. Using a different pain scale, 50% of
patients thought pain was less than that of biopsy, 40% patients
thought it was comparable and 10% patients thought it
was worse.
Many authors report low or moderate rates of complications
following FM implantation and conclude that TRUS-guided
implantation of FMs is safe and well tolerated in the majority of
patients.23,24,28–30 One might expect a higher proportion of
complication rates with such an invasive procedure. In general,
these studies are based on retrospective voluntary patient
reporting and therefore, less serious side effects may have been
underreported. Another study by Loh et al31 suggests that the
risk from FM implantation is underestimated. They report an
infective complication rate of 5.6% minimum from 297 patients
who underwent TR FM implantation, which is similar to that
reported for prostate biopsy complication rates.32
Moman et al33 compared TR and TP routes of implantation in
402 and 512 patients, respectively. Toxicity and subsequent
marker migration were similar. They have since continued to use
the TP route and have omitted the use of antibiotic therapy since
reporting their ﬁndings and report no infections several months
following. It would be reasonable to suppose that TR implan-
tation would result in a higher incidence of infection, particu-
larly when no rectal evacuation is employed. However, the
evidence does not seem to suggest this. This may be due to the
use of prophylactic antibiotic therapy. A signiﬁcant saving and
beneﬁt to the patient could be realized if TP implanting removed
the need for antibiotics, as suggested by Moman et al.33 Indeed,
the beneﬁts of reducing the need for antibiotics may be more far
reaching. Recent studies have demonstrated increasing rates of
antibiotic-resistant infection following TR intraprostatic proce-
dures, suggesting TP techniques may become more frequent in
the future.32,34
Assuming the use of antibiotics is standard, there is no evidence
to recommend one technique over the other. Based on the ev-
idence presented, both approaches are safe and well tolerated. In
clinical practice, the choice may be pragmatic and pre-
determined by the facilities and expertise available. Those with
prostate brachytherapy expertise and capacity may choose the
TP route, while those employing the skills of a biopsy clinic may
rely on the TR route. Factors common to both should be
standardized for the purpose of FM implantation, such as use of
enemas, anaesthesia, patient follow-up, placement of markers
and timing of implant prior to CT planning.
NUMBER AND TYPES OF FIDUCIAL MARKERS
FMs exist in a variety of shapes, sizes and materials and are
commercially available from a variety of vendors. Gold markers
are by far most frequently used for prostate IGRT. This is due to
the fact that they are widely available and are visible using MVor
kV image guidance. The basic speciﬁcation for an FM includes
radio-opacity for a given imaging modality (or preferably
a number of imaging modalities), that they are readily available
and that they are not prohibitively expensive.
This review elicited only one study speciﬁcally comparing types
of markers. Fonteyne et al35 investigated ﬁve different gold FMs.
They observed a better correlation between automatic CBCT
image-matching results and manual match results for the largest
FM, which was 20mm3 0.75mm, than for smaller FMs, sug-
gesting that larger markers may result in more consistent setup
data when comparing automatic and manual alignment. How-
ever, they also state the largest FM resulted in increased image
artefact. Artefact created by FMs on CT and CBCT is one of the
main disadvantages of using gold or entirely metallic markers
and may add to the degree of uncertainty associated with con-
touring and matching the prostate36 and may also result in in-
accurate treatment planning.37 One study suggests that platinum
is superior to gold in terms of its visibility on MRI and therefore
preferable as an aid for CT/MRI registration.38 This would have
the disadvantage of being more expensive than gold.
Non-metallic FMs have been around for a number of years and
claim to overcome the problem of metal-induced image arte-
facts. Despite this, in the evidence presented in this review, little
attention has been given to what effect FMs may have on the
dose distribution within the prostate. Dose and effects on dose
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distribution require modelling and measurement using geo-
metrically appropriate phantoms and techniques and therefore,
a full discussion is beyond the scope of this review. However,
there is a growing body of evidence on the dosimetric con-
sequences of various types of prostatic FMs. The effect may be
minimal, but some reports suggest that using gold FM dose may
be reduced by as much as 20% using photons39 and reduced by
up to 85% in proton therapy in the area immediately around
the FM.40
Many authors have reported studies based on the use of three or
four implanted gold markers.6,7,9,12,14,41 Most studies employ
three FMs placed in a 3D triangular arrangement to facilitate
assessment in the three cardinal directions (Figure 2).
Using gold FM coils, de Boer et al42 evaluated the impact of the
number of markers on matching and concluded that two ac-
curately locate the prostate if adequately spaced. Other inves-
tigators favour three or more markers in the event that one or
more migrate or are somehow lost.43
Nickel–titanium stents based on those used in the management
of urinary obstruction have been adapted and tested for feasi-
bility in prostate IGRT. They are visible on kV and MV images,
create no artefact on CT and are suitable for MRI.44 Further
evidence is needed to justify the complex surgical procedure and
associated risks required to implant these.
OTHER TYPES OF MARKER
Real-time target tracking has been developed and used clinically
using electromagnetic transponders.45,46 Radiofrequency-
emitting transponders are implanted into the prostate similar
to FMs. They are detected and monitored by an external mag-
netic array linked to the treatment room and located in relation
to the isocentre and couch corrections applied. This system
addresses intrafraction motion and theoretically eliminates op-
erator subjectivity associated with image analysis. No ionizing
radiation is received by the patient; however, this also means
there is no radiographic record of treatment and no assessment
of bladder, rectum or SV position is possible. Routine use of this
technology is expensive.
An alternative type of surrogate ﬁrst described by Shchory et al47
was clinically evaluated by de Kruijf et al,48 who used radioactive
iridium-192 as an implanted tracer in 20 patients. They report
this approach as feasible and safe. With the exception of reduced
image artefact, no particular advantages are apparent over inert
FMs. Given the additional radiation dose received by the patient,
and the additional precautionary measures required during
implantation, this method is not widely used.
Three gold markers as per Figure 2 are most commonly used.
Whatever type and arrangement is used, each institution should
be consistent, use standardized procedures and develop expertise
in their chosen approach. Non-metallic markers offer an at-
tractive alternative in terms of reduced cost, reduced image ar-
tefact and potentially reduced dosimetric consequences and
should be further investigated.
PROSTATE FIDUCIAL MARKER MIGRATION
The efﬁcacy of FMs for prostate IGRT is based on the as-
sumption that each marker will remain ﬁxed in position be-
tween planning and treatment and for the duration of
radiotherapy. True migration of FMs is likely rare and when it
does occur, the effect is minimal or negligible. Prostate gland
distortion before or during radiotherapy can occur owing to: (1)
post-implant oedema or bleeding, (2) changes in surrounding
organs at risk (OARs) and (3) shrinkage due to androgen dep-
rivation therapy.
A number of reports focused on this issue29,49–52 and collectively
evaluated a combined total of 144 patients with between 3 and 5
gold FMs. Each group recorded intermarker distance (IMD) as
a measure of FM migration, with the exception of Delouya
et al,51 who compared the 3D position of the FMs from planar
imaging with that at planning. Mean migration observed was
between 0.8mm (5/20.3mm SD)52 and 1.2mm (60.2mm
SD),49 (60.6mm SD).51 Pouliot et al29 report a mean SD of
1.3mm (range 0.44–3.04mm).
From their study of 453 patients, van der Heide et al12 report
minimal changes in IMD, demonstrating that markers are stable
in relation to each other and can be detected accurately.
In general, the evidence suggests that FM migration is not sig-
niﬁcant but raises a number of issues to consider when us-
ing FMs.
Kupelian et al50 highlight one such issue when they observed two
patients demonstrating IMD variation where the SD was.4mm
(maximum 4.2mm). In each case, one particular IMD varied
owing to variations in rectal ﬁlling. The proportion of IMD
variation contributed by actual migration in such cases is difﬁ-
cult to establish. Migration may not reliably be measured unless
all other surrounding physical conditions remain constant. Such
cases, as observed by Kupelian et al,50 demonstrate that if the
prostate has changed shape, the inconvenient reality is this
Figure 2. Three gold fiducial markers detected on anteropos-
terior megavoltage electronic portal imaging.
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cannot be corrected by standard IGRT conventions with or
without the use of FMs. Deformable image registration and
adaptive planning strategies are required to address this prob-
lem, a detailed discussion of which is beyond the scope of this
review, but an overview of these topics is given by Maintz and
Viergever,53 Kashani et al54 and Kupelian and Meyer.55
Pouliot et al29 measured IMDs of 3 gold implanted markers in
11 patients using orthogonal MV image pairs. They observed
a time trend in three patients where the distance between all
three markers decreased over the course of radiotherapy, sug-
gesting overall shrinkage of the prostate. Volume reduction was
subsequently conﬁrmed on CT for one of the patients. They
suggest that all three patients received neoadjuvant hormones,
which may have caused prostate shrinkage. However, shrinkage
was not observed in all patients who received hormone therapy,
indicating there are other inﬂuencing factors. Details of the
timing of ﬁducial implantation were not given. Anatomical or
physiological changes have the potential to cause or mimic
marker migration and therefore, approaches minimizing this
should be considered. Oedema and inﬂammatory responses
initiated during implantation may still be present during CT
planning. These may then resolve before or during treatment,
resulting in volume changes or deformation. This could po-
tentially alter the position of the FMs and introduce systematic
positioning error. This is supported by the ﬁndings of Delouya
et al.51 Of 31 patients, 7% of patients demonstrated “signiﬁcant
shrinkage”. The maximum reduction was 95% of the volume at
planning. They observed that of 31 patients included in their
study, 23 patients had their CT planning scan the same day as
FM implantation and had larger migrations than those whose
CT planning was later than the day of implantation. The actual
differences in migration are not reported, but this group sub-
sequently changed their local practice to allow a minimum of at
least 3 days between implantation and CT planning.
FM migration can occur, but prostate gland deformation is more
commonly observed. However, in clinical practice, it is unlikely
that migration or deformations are signiﬁcant limitations to the
utilization of FMs for prostate radiotherapy, but standardized
approaches to minimize known causes should be incorporated.
IMAGING MODALITIES
Evidence supporting the use of prostate FM IGRT is largely
based on the use of 2D imaging (MV or kV). There is signiﬁ-
cantly less evidence available on the use of FMs with 3D imaging
such as CBCT or ultrasound.
In a study of 36 patients, Barney et al56 compared their standard
technique of kV imaging of FMs with CBCT soft-tissue align-
ment to ascertain the degree of correlation. They reported mean
and absolute differences in setup data between the two modal-
ities and observed a mean difference of 3mm in two of three
dimensions, which affected target coverage in 25% of all shifts
observed. In a larger study, Gill et al investigated interfraction
prostate displacement in 333 patients and compared MV EPI
and FMs with KV imaging of FMs. They found a statistically
signiﬁcant smaller setup error with MV imaging in all directions,
but particularly so in the AP direction.41 It is possible that setup
error was underestimated owing to the inferior image quality of
MV vs kV images. This would be more apparent on lateral
images (used to assess the AP position) owing to increased X-ray
attenuation. Regardless of the reasons, the differences reported
by these investigators may result in different planning margins
being derived depending on which imaging modality is used to
generate treatment setup data. According to Gill et al,41 this may
be most likely in the AP direction which will impact clinically at
the prostate–rectal interface. This is where the CTV–PTV mar-
gin is often reduced to avoid rectal toxicity, thus increasing this
risk of missing the posterior aspect of the prostate or overdosing
the rectal wall.
Soft-tissue contrast is not optimal on CT or CBCT; therefore, it
can be reasoned that accurately identifying the position of the
prostate based on CBCT is a subjective process and there is
evidence to support this.57,58,36 A key issue when using CBCT
without FM is interobserver variability due to poor soft-tissue
contrast, which can introduce a source of systematic error in the
application of treatment setup corrections, which by deﬁnition
contribute to the error in margin calculations. FMs serve to
eliminate a degree of the uncertainty associated with soft-tissue
alignment, but cannot overcome other contributory factors in-
cluding the variations associated with imaging modality.56,41
When used with 2D imaging alone, FMs do not enable visual-
ization of the target or assessment of organ motion or de-
formation. It has been reported that a large rectal volume is
predictive of poorer treatment outcome59 and therefore requires
assessment in conjunction with accurate prostate alignment to
ensure treatment efﬁcacy. In this regard, CBCT may be prefer-
able to 2D imaging, or it could be reasoned, should be used as an
adjunct to planar imaging with FMs. While the accuracy of
a CBCT prostate match may be inherently variable, it will
nevertheless reveal gross anatomical differences in rectal and also
bladder volumes that may signiﬁcantly alter the planned dose
distribution to the target and/or OARs. This information alerts
therapists to take action to improve this, thereby optimizing
treatment delivery. This review found no studies directly com-
paring ultrasound detection of FM with detection using another
imaging modality. This may be because FMs are not easily vi-
sualized on transabdominal ultrasound (TAUS).35 Further re-
search into the use of in-room ultrasound techniques for FM
IGRT is warranted.
There are limited studies on the use of FMs with SC imaging and
six degrees of freedom capability. Using the ExacTrac® 6D IGRT
system (Brainlab AG, Feldkirchen, Germany), Shi et al60 report
mean shifts of 0.2, 21.09 and 20.93mm in the lateral, longi-
tudinal and vertical directions, respectively, with corresponding
rotational errors of 0.25, 0.1 and 0.02° for all fractions in
43 patients with PCa with FMs. Rotational corrections were not
applied. Those exceeding 2° were investigated and repositioned.
In a series of 40 patients, Fuller et al61 compared treatment setup
errors derived from in-room TAUS imaging of the prostate with
those from kV SC images of prostate FMs for radiotherapy ver-
iﬁcation. As in Barney et al, the purpose of this comparison study
was not to establish which modality was superior, although
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treatment was corrected and treated according to SC FM position.
They concluded that concordance of resulting TAUS prostate and
SC FM measurements was “poor” or “unacceptable” with 95% of
measures within 15mm.61 Numerous other groups have found
signiﬁcant differences in treatment setup data derived from TAUS
soft-tissue assessment compared with FM data from other mo-
dalities, greater variation within ultrasound data and ultrasound-
derived PTV margins may be up to 3–4 times smaller than those
reported in the literature.43,62,63 Fuller et al61 also provide a useful
narrative on the inherent difﬁculties of comparing IGRT modal-
ities which brieﬂy include the lack of an established ground truth
and the statistical inaccuracies of comparing data generated by
incomparable methods or devices.
The evidence presented here would suggest that treatment setup
error data, with or without the use of FMs, are not in-
terchangeable between imaging modalities and may generate
different planning margins for the same treatment site and
technique. Larger multicentre studies comparing standardized
IGRT methods are needed to establish a gold standard IGRT
approach that will enhance the beneﬁts of FMs.
With currently available IGRT solutions, it is likely that a com-
bined IGRT approach employing CBCT with FMs or CBCT in
addition to FMs and planar imaging will provide the best pos-
sible assessment of prostate position and changes in OARs.
CLINICAL IMPACT OF PROSTATE FIDUCIAL
MARKER IMAGE-GUIDED RADIOTHERAPY
Many studies demonstrate that the use of FMs improves prostate
targeting during image-guided (IG) external beam radiotherapy.
It is less clear what clinical impact this has in terms of patient-
reported toxicity and overall survival and no prospective ran-
domized controlled trials have been performed.
Paluska et al,11 Cheung et al64 and Skarsgard et al65 have all
demonstrated the feasibility of reducing PTV margins with the
use of FMs. Paluska et al proposed that a 10-mm CTV–PTV
margin used with daily bone setup could be reduced to 7mm
using FMs and daily imaging. Furthermore, they observed better
CTV coverage using FMs and reduced margins compared with
bony setup plus a 10-mm margin. Toxicity was not reported in
this study. However, by further limiting dose to normal sur-
rounding structures, the PTV margin reduction theoretically
reduces toxicity, since reducing the volume of rectum receiving
60Gy or more has been shown to be associated with a reduction
in rectal toxicity.66 In addition, reducing the PTV facilitates dose
escalation and may improve progression-free survival.
Cheung et al64 prospectively assessed acute toxicity. They delivered
a hypofractionated IMRT boost using patient-speciﬁc margins, the
average of which was 3, 3 and 4mm in the lateral, superior–inferior
and AP directions, respectively. These margins were based on their
assessment of intrafraction prostate motion using daily FM IGRT.
They reported acceptable acute toxicity; however, Grade 3 genito-
urinary toxicity (National Cancer Institute Common Toxicity
Criteria v. 2.0) was reported in 3 out of the 33 patients included in
the study. In a more recent retrospective study, Takeda et al67 an-
alyzed the outcome data for 141 patients treated using high-dose
FM IG-IMRT and reported that treatment is well tolerated based
on 5-year outcomes. Cheung et al and Takeda et al report ﬁndings
which are reassuring in terms of demonstrating acceptable toxicity
using reduced margins, but neither had a non-FM IGRT control
group; therefore, it is unclear what contribution the use of FMs
made to the outcome data.
The impact of IG-IMRT with FMs and reduced margins was
compared with IMRT without FM IGRT by Chung et al68 in
a prospective non-randomized study of 25 patients. Radiation
Therapy Oncology Group and Common Terminology for Ad-
verse Events scores for rectal and bladder toxicity were consis-
tently lower in the FM IG-IMRT group. These ﬁndings are
partially supported by Singh et al69 in relation to rectal toxicity
in a large patient cohort, where 154 patients had FM IGRT and
128 patients had non-IGRT. There was no difference in reported
urinary symptoms in each group.
Zelefsky et al,70 Kok et al71 and Sveistrup et al72 compared large
cohorts of patients retrospectively, where the main difference
was the use or not of FMs for image guidance. All report
improvements in urinary and gastrointestinal toxicity for the
FM groups. Kok et al observed a reduced incidence of gastro-
intestinal toxicity despite a higher dose of 78Gy in the FM group
compared with 74Gy in the non-FM group, but no difference in
biochemical failure-free survival was observed. Sveistrup et al
observed a biochemical progression-free advantage for the FM
group, but this was not statistically signiﬁcant.
There is convincing evidence that FM IGRT improves the ac-
curacy of prostate targeting and some evidence that using FM
IGRT reduces treatment-related toxicity without compromising
treatment outcomes; therefore, it is unlikely a prospective ran-
domized control trial comparing FM IGRT with non-FM IGRT
will ever be performed.
PROSTATE CALCIFICATIONS AS FIDUCIAL
MARKERS
The risks of prostate FM implantation described earlier are
justiﬁed, provided a similar non-invasive approach does not
exist. Alternatives that remove the need for artiﬁcial FMs would
also eliminate the use of anaesthesia and antibiotics and save
signiﬁcant health service time and resources. For example, MRI-
based radiotherapy using MRI linear accelerators may in the
future offer a non-invasive and also non-ionizing approach to
prostate IGRT which may not require FMs.
Prostate calciﬁcations (PCs) are small ovoid or round bodies
impregnated with calcium phosphate and calcium carbonate
and are reported to be present in almost 90% of prostatectomy
specimens.73 It has been reported that up to 35% of patients
undergoing prostate radiotherapy have calciﬁcations visible on
CBCT.74 PCs may be detected coincidentally from histological or
radiological ﬁndings, and patients are often asymptomatic. The
signiﬁcance of PCs is not well understood, but there is some
evidence to suggest an association of PCs and prostatic in-
ﬂammation, lower urinary tract symptoms and PCa.75–77 Their
relevance here is that PCs visible on radiographic images may
present a natural alternative to surgically implanted markers.
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Zeng et al74 investigated the stability of PCs with a view to using
them as a surrogate for prostate position during IGRTand found
that they were stable. A subsequent study recommended the use
of central intraprostatic PCs for IGRT.78 More encouraging is
the work by Kim et al,79 who used PC mismatch as the end point
in assessing similarity metrics on CBCT. They found the pres-
ence of PCs increased the success of CT/CBCT image registra-
tions. These ﬁndings are based on 4, 10 and 14 patients,
respectively, and therefore, investigation using larger patient
numbers is warranted.
Given the potential for reducing risk and inconvenience to
patients of surgically implanted FMs and the potential cost sav-
ings, PCs as a natural FM justiﬁes more in-depth research. A
prospective feasibility study investigating this is under way at our
centre. The study Calciﬁcations as an Alternative to Surgically
Implanted Fiducial Markers for Prostate IGRT will directly
compare FMs and PCs for the purpose of online image matching
and correction. This study will also prospectively collect patient
feedback regarding their experience of FM implant.
CONCLUSION
FMs present a good surrogate for the position of the prostate
and may reﬂect prostate gland motion or deformation. Changes
in rectal and bladder volume, prostate deformation and SV
motion are not detected by FM imaging alone.
A combination of FM alignment and soft-tissue analysis is
currently the most effective and widely available approach to
ensuring accuracy in prostate IGRT. Standardized clinical pro-
tocols are needed to enable comparison of treatment accuracy
data, toxicity and treatment outcomes. Further research into the
use of TAUS with FMs and the dosimetric implications of FMs is
warranted.
There is a lack of randomized studies on the beneﬁts of FM
IGRT that control for other parameters such as the effect of
hormone therapy and pre-existing urinary symptoms.
Marker migration is minimal. Anatomical or physiological
changes such as rectal and bladder ﬁlling may cause deformation
or distortion of the prostate gland and result in the apparent
migration of FMs. Other factors such as the timing of CT
planning following implantation and the use of androgen dep-
rivation therapy may inﬂuence the apparent stability of markers.
Implantation of FMs is well tolerated, but surgical techniques
and toxicity data require standardization. Development of FM
implantation techniques that facilitate a reduction in the use of
prophylactic antibiotic therapy should be considered in light of
the global problem of multiresistant bacteria.
Organ deformation and conﬂicting alignment of multiple targets
requires 3D veriﬁcation, deformable image registration and
adaptive planning techniques and cannot be addressed by con-
ventional IGRT with or without the use of FMs.
Despite the advent of MR-guided radiotherapy, such technology
is unlikely to become the standard of care in most centres for
some time. Also, while superior in terms soft-tissue contrast,
MRI is contraindicated for some patients and since dose esca-
lation, hypofractionation and stereotaxy are already here, the
authors suggest that the future of FMs in prostate IGRT is secure
for the foreseeable.
It is clear from the evidence that FMs are a useful aid to en-
hancing the accuracy of prostate IGRT. However, given the issues
in relation to FM implantation including cost, risk of infection
and antibiotic resistance, there is merit, perhaps also a duty, to
investigate a natural alternative to FMs that has the potential to
beneﬁt a signiﬁcant proportion of the PCa population.
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